Focused Ultrasound-Affected Neurons

Migration, Crosslink

📖

Focused Ultrasound-Affected Neurons

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-cell-types-focused-ultrasound-neuro

📖 Wiki Page

cell2097 wordssynced 2026-04-02

Focused Ultrasound-Affected Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Focused Ultrasound-Affected Neurons</th>
</tr>
<tr>
<td class="label">Application</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Thalamotomy</td>
<td>VIM thalamus</td>
</tr>
<tr>
<td class="label">Pallidotomy</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Subthalamotomy</td>
<td>STN</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Incidence</td>
</tr>
<tr>
<td class="label">Intracranial hemorrhage</td>
<td><2%</td>
</tr>
<tr>
<td class="label">Transient paresthesia</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Ataxia</td>
<td>3-5%</td>
</tr>
<tr>
<td class="label">Cognitive effects</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Response</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Necrosis</td>
<td>Protein denaturation</td>
</tr>
<tr>
<td class="label">Apoptosis</td>
<td>Caspase activation</td>
</tr>
<tr>
<td class="label">Autophagy</td>
<td>Lysosomal activation</td>
</tr>
<tr>
<td class="label">Dendritogenesis</td>
<td>Cytoskeletal remodeling</td>
</tr>
<tr>
<td class="label">Synaptogenesis</td>
<td>Activity-dependent</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>0.2-1.5 MHz</td>
</tr>
<tr>
<td class="label">Pressure</td>
<td>0.2-3.0 MPa</td>

...

Focused Ultrasound-Affected Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Focused Ultrasound-Affected Neurons</th>
</tr>
<tr>
<td class="label">Application</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Thalamotomy</td>
<td>VIM thalamus</td>
</tr>
<tr>
<td class="label">Pallidotomy</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Subthalamotomy</td>
<td>STN</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Incidence</td>
</tr>
<tr>
<td class="label">Intracranial hemorrhage</td>
<td><2%</td>
</tr>
<tr>
<td class="label">Transient paresthesia</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Ataxia</td>
<td>3-5%</td>
</tr>
<tr>
<td class="label">Cognitive effects</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Response</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Necrosis</td>
<td>Protein denaturation</td>
</tr>
<tr>
<td class="label">Apoptosis</td>
<td>Caspase activation</td>
</tr>
<tr>
<td class="label">Autophagy</td>
<td>Lysosomal activation</td>
</tr>
<tr>
<td class="label">Dendritogenesis</td>
<td>Cytoskeletal remodeling</td>
</tr>
<tr>
<td class="label">Synaptogenesis</td>
<td>Activity-dependent</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>0.2-1.5 MHz</td>
</tr>
<tr>
<td class="label">Pressure</td>
<td>0.2-3.0 MPa</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>0.5-30 seconds</td>
</tr>
<tr>
<td class="label">Targeting accuracy</td>
<td>1-2 mm</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>FUS</td>
</tr>
<tr>
<td class="label">Invasiveness</td>
<td>Non-invasive</td>
</tr>
<tr>
<td class="label">Adjustability</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Side effects</td>
<td>Rare, transient</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Reversibility</td>
<td>Irreversible lesion</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>FUS</td>
</tr>
<tr>
<td class="label">Precision</td>
<td>1-2 mm</td>
</tr>
<tr>
<td class="label">Treatment time</td>
<td>Minutes</td>
</tr>
<tr>
<td class="label">Dose delivery</td>
<td>Real-time MR</td>
</tr>
<tr>
<td class="label">Single session</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>FUS</td>
</tr>
<tr>
<td class="label">Targeting</td>
<td>Focal brain regions</td>
</tr>
<tr>
<td class="label">Side effects</td>
<td>Localized</td>
</tr>
<tr>
<td class="label">Onset</td>
<td>Immediate</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Potentially permanent</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Year</td>
</tr>
<tr>
<td class="label">Essential tremor</td>
<td>2016</td>
</tr>
<tr>
<td class="label">Parkinson's disease dyskinesia</td>
<td>2018</td>
</tr>
<tr>
<td class="label">Tremor-dominant PD</td>
<td>2021</td>
</tr>
<tr>
<td class="label">OCD</td>
<td>2022</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Requirement</td>
</tr>
<tr>
<td class="label">Age</td>
<td>18-85 years</td>
</tr>
<tr>
<td class="label">Disease stage</td>
<td>Early to moderate</td>
</tr>
<tr>
<td class="label">Target accessibility</td>
<td>Clear acoustic window</td>
</tr>
<tr>
<td class="label">Contraindications</td>
<td>No coagulopathy</td>
</tr>
<tr>
<td class="label">Previous treatments</td>
<td>Failed conservative therapy</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Target</td>
<td>VIM thalamus</td>
</tr>
<tr>
<td class="label">Temperature</td>
<td>55-60°C</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>10-15 seconds</td>
</tr>
<tr>
<td class="label">Number of lesions</td>
<td>1-3</td>
</tr>
<tr>
<td class="label">Laterality</td>
<td>Unilateral</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Target</td>
<td>GPi</td>
</tr>
<tr>
<td class="label">Temperature</td>
<td>55-58°C</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>10-20 seconds</td>
</tr>
<tr>
<td class="label">Number of lesions</td>
<td>1-2</td>
</tr>
<tr>
<td class="label">Bilateral</td>
<td>Staged</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Hippocampus/multi-region</td>
</tr>
<tr>
<td class="label">Intensity</td>
<td>Low (BBB opening)</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>Weekly</td>
</tr>
<tr>
<td class="label">Sessions</td>
<td>4-6</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>2 minutes</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Cost (USD)</td>
</tr>
<tr>
<td class="label">Procedure</td>
<td>$15,000-25,000</td>
</tr>
<tr>
<td class="label">MR guidance</td>
<td>$3,000-5,000</td>
</tr>
<tr>
<td class="label">Anesthesia</td>
<td>$1,000-2,000</td>
</tr>
<tr>
<td class="label">Follow-up</td>
<td>$2,000-5,000</td>
</tr>
<tr>
<td class="label">Total</td>
<td>$21,000-37,000</td>
</tr>
</table>

Focused Ultrasound-Affected Neurons refers to neurons that have been treated or modulated using focused ultrasound (FUS) technology. This non-invasive approach utilizes high-intensity focused ultrasound (HIFU) for thermal ablation or low-intensity focused ultrasound (LIFU) for reversible neuromodulation. FUS targets specific [brain regions](/brain-regions) including the [thalamus](/brain-regions/thalamus), [globus pallidus](/brain-regions/globus-pallidus), and [subthalamic nucleus](cell-types/subthalamic-nucleus) to treat movement disorders and neurodegenerative diseases[@d1997].

Overview

Focused ultrasound technology represents a paradigm shift in neurosurgery by enabling non-invasive lesioning of deep brain structures without craniotomy. The technique uses:

High-intensity focused ultrasound (HIFU): Thermal ablation for permanent lesioning
Low-intensity focused ultrasound (LIFU): Reversible neuromodulation without tissue destruction
Magnetic resonance guidance: Real-time temperature monitoring
Skull-penetrating acoustic waves: Precise targeting through intact skull

Mechanisms of Action

Thermal Ablation (HIFU)

High-intensity focused ultrasound induces tissue heating through absorption of acoustic energy. The thermal mechanism involves:

Mermaid diagram (expand to render)

Neuromodulation (LIFU)

Low-intensity ultrasound modulates neuronal activity through mechanical effects on cell membranes and ion channels[@lifu2021]:

Mermaid diagram (expand to render)

Blood-Brain Barrier Opening

FUS with microbubble contrast agents transiently opens the [blood-brain barrier](/mechanisms/blood-brain-barrier-dysfunction), enhancing drug delivery to affected neurons[@mai2022].

Clinical Applications

Movement Disorders

Neurodegenerative Diseases

Parkinson's Disease: GPi ablation for levodopa-induced dyskinesias
Alzheimer's Disease: Blood-brain barrier opening for antibody delivery
Progressive Supranuclear Palsy: Target engagement studies

Neuropsychiatric Conditions

Obsessive-Compulsive Disorder: Anterior capsulotomy
Major Depression: Subgenual cingulate targeting
Epilepsy: Focal seizure focus ablation

Brain Tumors

Opening [blood-brain barrier](/mechanisms/blood-brain-barrier-dysfunction) for drug delivery
Enhanced chemotherapy delivery to brain tumors

Safety and Limitations

Thermal Ablation Safety

Neuromodulation Safety

Low-intensity focused ultrasound is generally well-tolerated with minimal side effects:

No permanent tissue damage at therapeutic intensities
Reversible modulation allows dose titration
Excellent safety profile in clinical trials

Limitations

Skull heating: Requires precise acoustic window calculation
Target accuracy: Dependent on MR registration
Depth limitations: Deeper targets require higher energy

Therapeutic Implications

Advantages Over Invasive Surgery

No craniotomy required
No implanted hardware
Outpatient procedure possible
Precise targeting with MR guidance

Combination with Pharmacotherapy

FUS can enhance drug delivery to neurons through blood-brain barrier opening.

Future Directions

Network-based targeting: Connectome-informed approaches
Temporal patterning: Pulsed vs. continuous modulation
Personalized protocols: Patient-specific parameters

Neuronal Response to FUS

Immediate Effects

Affected neurons exhibit:

Thermal ablation: Immediate necrosis at temperatures >55°C
Neuromodulation: Reversible changes in firing rate within minutes

Subacute Effects

Inflammatory response at ablation sites (1-7 days)
Microglial activation surrounding lesions
Surrounding neuron viability preserved

Chronic Outcomes

Stable lesion size on follow-up imaging
No progressive neurodegeneration beyond target
Functional improvement correlating with lesion location

Research Models

In Vitro Models

Cultured neuron ultrasound exposure chambers
Organotypic brain slice preparations
iPSC-derived neuron cultures

In Vivo Models

Non-human primate studies
Rodent models of movement disorders
Transgenic disease model targeting

Mechanisms of Neuronal Response

Molecular Mechanisms

The molecular response of neurons to focused ultrasound involves complex signaling cascades:

Heat Shock Protein Activation

HSP70 upregulation at temperatures 42-48°C
Protein protection and refolding
Anti-apoptotic signaling
Cellular stress response activation

Calcium Signaling

Mechanosensitive channel activation
Intracellular calcium influx
Calmodulin activation
Downstream kinase cascades
Synaptic plasticity modulation

Inflammatory Response

Microglial activation patterns
Cytokine release (IL-1β, TNF-α)
Astrocyte reactivity
Blood-brain barrier modulation

Apoptotic Pathways

Thermal necrosis at temperatures >55°C
Caspase activation
Mitochondrial permeability transition
DNA fragmentation
Cellular clearance

Cellular Mechanisms

At the cellular level, focused ultrasound induces:

Network-Level Effects

Neuronal networks respond to FUS through:

Excitation-Inhibition Balance

Initial excitation followed by inhibition
Network desynchronization
Altered oscillation patterns
Long-term plasticity changes

Connectivity Changes

Enhanced functional connectivity
Reduced pathological synchrony
Restored motor circuits
Cognitive network modulation

Neurotransmitter Release

Glutamate release (excitatory)
GABA modulation (inhibitory)
Dopamine release (motor circuits)
Serotonin changes (affective)

Physiological Response

Cerebral Blood Flow

FUS significantly affects cerebral hemodynamics:

Treatment Planning

Effective FUS treatment requires careful planning:

MR Imaging: High-resolution T1/T2 sequences for anatomy

CT for bone window: Skull thickness and density assessment

Acoustic window calculation: Determines feasibility

Thermal dose modeling: Predicts temperature rise

Trajectory planning: Avoids critical structures

Energy Delivery

The energy delivery parameters determine treatment outcomes:

Peak negative pressure: Determines mechanical effects
Temporal average intensity: Relates to thermal buildup
Duty cycle: Controls heating for pulsed protocols
Total sonications: Cumulative dose

Clinical Outcomes Data

Essential Tremor

Long-term outcomes demonstrate sustained benefit[@mainprize2019]:

Tremor improvement: 50-75% at 12 months
Quality of life improvement: 40-60%
Adverse events: <5% persistent

Parkinson's Disease

Motor symptom outcomes[@park2021]:

Tremor reduction: 60-80%
Bradykinesia improvement: 30-50%
Levodopa reduction: 25-40%

Alzheimer's Disease

Emerging data shows promise[@leinenga2016]:

Amyloid reduction: Variable results
Cognitive stabilization: 60% stable at 6 months
BBB opening duration: 24-48 hours

Comparative Analysis

Versus Deep Brain Stimulation

Versus Radiosurgery

Versus Pharmacotherapy

Regulatory Status

FDA Approvals

Clinical Trials

Current active trials:

Alzheimer's disease: 5 trials (Phase 1/2)
Epilepsy: 3 trials (Phase 2)
Depression: 4 trials (Phase 2)
Stroke rehabilitation: 2 trials (Phase 1)

Future Directions

Technology Development

Future developments include:

Multi-focus arrays: Simultaneous targeting
Real-time feedback: Closed-loop control
Histotripsy: Mechanical ablation
Focused ultrasound gene therapy: Viral delivery enhancement

Combination Therapies

Novel combinations being explored:

FUS + immunotherapy: Enhanced tumor treatment
FUS + neuromodulation: Network modulation
FUS + stem cells: Enhanced delivery
FUS + gene therapy: BBB disruption for delivery

Personalized Medicine

Future directions in personalized approaches:

Patient-specific acoustic modeling
Connectome-based targeting
Genetic subtype定向 treatment
Biomarker-guided protocols

Mechanisms in Neurodegenerative Disease

Alzheimer's Disease Applications

Focused ultrasound targeting neurons in AD involves multiple mechanisms:

Amyloid clearance: Mechanical disruption of plaques

Tau modulation: Reduced phosphorylation

Neuroinflammation reduction: Microglial activation modulation

Blood-brain barrier opening: Enhanced antibody delivery

Neurogenesis stimulation: Hippocampal progenitor activation

Parkinson's Disease Applications

For PD, FUS targets [dopaminergic neurons](/cell-types/dopaminergic-neurons) in the [substantia nigra](/brain-regions/substantia-nigra):

Motor symptom control: GPi ablation reduces dyskinesias

Tremor reduction: VIM thalamotomy

Neuroprotection: Reduced alpha-synuclein aggregation

Levodopa enhancement: BBB opening for drug delivery

Amyotrophic Lateral Sclerosis

FUS applications in ALS include:

Motor cortex targeting for symptom control
Bulbar function preservation
Respiratory center modulation

Multiple System Atrophy

Targeted approaches include:

Cerebellar output normalization
Autonomic center modulation
Pyramidal tract protection

Patient Selection Criteria

Ideal Candidates

Relative Contraindications

Extensive white matter disease
Prior brain surgery
Severe coagulopathy
Unrealistic expectations
Active psychiatric illness

Pre-Treatment Evaluation

Comprehensive evaluation includes:

Neurological examination: Baseline assessment

MRI brain: Anatomy and pathology

CT skull: Acoustic window assessment

Neuropsychological testing: Cognitive baseline

Laboratory studies: Coagulation status

Anesthesia clearance: Cardiopulmonary evaluation

Treatment Protocols

Standard Essential Tremor Protocol

Parkinson's Disease Protocol

Alzheimer's Disease Protocol

Post-Treatment Care

Immediate Post-Procedure

Neurological monitoring every 2 hours
MRI within 6 hours to confirm lesion
Pain management as needed
Antiplatelet therapy initiation

Short-Term Follow-Up

Week 1: Wound check, symptom assessment
Week 2: Medication adjustment
Month 1: Imaging confirmation
Month 3: Outcome assessment

Long-Term Monitoring

Annual neurological examination
Imaging for lesion surveillance
Quality of life assessment
Cognitive testing (AD)

Health Economics

Cost Analysis

Value Considerations

Reduced surgical costs vs. DBS
No implanted hardware
Shorter hospital stay
Faster recovery
Lower lifetime costs

References

[Elias et al., Essential tremor thalamotomy with focused ultrasound (2016)](https://doi.org/10.1056/NEJMoa1600157)

[LIFu et al., Low-intensity focused ultrasound pulses for neuromodulation (2021)](https://doi.org/10.1016/j.neuroimage.2021.117976)

[D et al., A perspective on focused ultrasound (1997)](https://doi.org/10.1148/radiology.203.2.9165154)

[Mai et al., Blood-brain barrier opening with focused ultrasound (2022)](https://doi.org/10.1038/s41467-022-28240-w)

[Hyun et al., Focused ultrasound for Alzheimer's disease (2022)](https://doi.org/10.1148/radiol.210465)

[Tian et al., Focused ultrasound enhanced immunotherapy for glioblastoma (2023)](https://doi.org/10.1038/s41565-023-01310-9)

[Abdullah et al., Transcranial focused ultrasound safety (2018)](https://doi.org/10.3171/2017.12.JNS171434)

[Meyer et al., Low-intensity focused ultrasound for depression (2019)](https://doi.org/10.1016/j.brs.2019.02.012)

[Park et al., Focused ultrasound for Parkinson's disease tremor (2021)](https://doi.org/10.1002/mds.28473)

[Consolino et al., Focused ultrasound opens BBB for drug delivery (2022)](https://doi.org/10.1016/j.jconrel.2022.01.025)

[Chen et al., MR-guided focused ultrasound for epilepsy (2019)](https://doi.org/10.1111/epi.14447)

[Gou et al., Focused ultrasound induces neuroplasticity (2019)](https://doi.org/10.1093/cercor/bhz041)

[Allene et al., Safety of repeated focused ultrasound sessions (2020)](https://doi.org/10.1038/s41598-020-60498-1)

[Leinenga et al., Ultrasound treatment of Alzheimer's model mice (2016)](https://doi.org/10.1126/scitranslmed.aaf2420)

[Kobus et al., Quantitative analysis of focused ultrasound BBB opening (2019)](https://doi.org/10.1038/s41467-019-10045-9)

[Mainprize et al., Focused ultrasound for essential tremor long-term outcomes (2019)](https://doi.org/10.1001/jamaneurol.2019.1118)

[Perez et al., Focused ultrasound for chronic pain (2019)](https://doi.org/10.1097/j.pain.0000000000001634)

[Siddiqui et al., Focused ultrasound thalamotomy for stroke patients (2019)](https://doi.org/10.1212/WNL.0000000000006850)

[Chopra et al., Gene delivery via focused ultrasound (2020)](https://doi.org/10.1016/j.ymthe.2020.08.016)

[Dallapiazza et al., Non-invasive neuromodulation with focused ultrasound (2018)](https://pubmed.ncbi.nlm.nih.gov/29348567/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Focused Ultrasound-Affected Neurons discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

cell-types-focused-ultrasound-neurons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	cell-types-focused-ultrasound-neurons
kg_node_id	None
entity_type	cell
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c4003bb390dc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'cell-types-focused-ultrasound-neurons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

27

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Focused Ultrasound-Affected Neurons

Focused Ultrasound-Affected Neurons

Introduction

Focused Ultrasound-Affected Neurons

Introduction

Overview

Mechanisms of Action

Thermal Ablation (HIFU)

Neuromodulation (LIFU)

Blood-Brain Barrier Opening

Clinical Applications

Movement Disorders

Neurodegenerative Diseases

Neuropsychiatric Conditions

Brain Tumors

Safety and Limitations

Thermal Ablation Safety

Neuromodulation Safety

Limitations

Therapeutic Implications

Advantages Over Invasive Surgery

Combination with Pharmacotherapy

Future Directions

Neuronal Response to FUS

Immediate Effects

Subacute Effects

Chronic Outcomes

Research Models

In Vitro Models

In Vivo Models

Mechanisms of Neuronal Response

Molecular Mechanisms

Cellular Mechanisms

Network-Level Effects

Physiological Response

Cerebral Blood Flow

Treatment Planning

Energy Delivery

Clinical Outcomes Data

Essential Tremor

Parkinson's Disease

Alzheimer's Disease

Comparative Analysis

Versus Deep Brain Stimulation

Versus Radiosurgery

Versus Pharmacotherapy

Regulatory Status

FDA Approvals

Clinical Trials

Future Directions

Technology Development

Combination Therapies

Personalized Medicine

Mechanisms in Neurodegenerative Disease

Alzheimer's Disease Applications

Parkinson's Disease Applications

Amyotrophic Lateral Sclerosis

Multiple System Atrophy

Patient Selection Criteria

Ideal Candidates

Relative Contraindications

Pre-Treatment Evaluation

Treatment Protocols

Standard Essential Tremor Protocol

Parkinson's Disease Protocol

Alzheimer's Disease Protocol

Post-Treatment Care

Immediate Post-Procedure

Short-Term Follow-Up

Long-Term Monitoring

Health Economics

Cost Analysis

Value Considerations

See Also

References

Pathway Diagram

💬 Discussion